Ultrasound-Guided External Oblique Intercostal Block Enters a Randomized Postoperative Analgesia Trial
Postoperative pain control after major laparoscopic upper abdominal surgery remains a central element of enhanced recovery pathways, and this BMJ Open protocol tests whether an ultrasound-guided bilateral external oblique intercostal block can reduce opioid need in the first 24 hours after surgery. The study is designed as a single-blind, parallel-group randomized controlled trial, with computer-generated permuted block randomization and allocation concealment built into the design. Block sizes of 4, 6, and 8 are used to preserve balance while limiting predictability. The focus is narrow and clinically practical: measure whether adding a regional analgesic technique to standard care can change immediate postoperative opioid consumption.
One sentence captures the clinical logic of the trial: opioid sparing is the endpoint that matters most in the first day after surgery.
A Design Built to Reduce Perioperative Noise
The protocol standardizes the anesthetic environment to keep analgesic comparisons as clean as possible. Every participant receives standardized general anesthesia and a uniform patient-controlled intravenous analgesia regimen, which should minimize differences in background pain control between study arms. In perioperative analgesia research, this kind of consistency matters because variable anesthetic technique, rescue medication patterns, and postoperative nursing practice can obscure a true block effect. By locking down those moving parts, the trial seeks to isolate the contribution of the external oblique intercostal block itself.
The primary outcome is objective: 24-hour opioid consumption. That choice strengthens the protocol because opioid use is less vulnerable than patient-reported scores to expectation effects and assessor bias. If the block meaningfully reduces opioid requirements, the signal should appear early, in the immediate postoperative period when pain is often most intense and opioid side effects are most clinically relevant.
Why This Block Could Matter After Upper Abdominal Surgery
The external oblique intercostal block is positioned to address somatic pain from laparoscopic upper abdominal procedures, where port sites and upper abdominal wall irritation often drive the need for analgesia despite minimally invasive access. Ultrasound guidance should improve anatomic precision and help deliver local anesthetic to the intended plane. In practical terms, that may translate into better chest and upper abdominal wall analgesia, less reliance on intravenous opioids, and potentially smoother early mobilization.
Regional anesthesia has long pursued two goals at once: pain relief and opioid reduction. The second goal has grown more urgent because opioid exposure after surgery can worsen nausea, sedation, delayed ambulation, and discharge readiness. A regional technique that lowers opioid consumption without adding complexity or instability would fit naturally into enhanced recovery after surgery pathways. This trial is explicitly structured to test that possibility rather than assume it.
Blinding Is Partial, and the Protocol Acknowledges It
The investigator who performs the block cannot be blinded, and that creates a real risk of performance bias. In a trial of this kind, the clinician delivering the intervention may behave differently, even unintentionally, and the absence of a sham comparator leaves subjective outcomes more exposed to expectation effects. The protocol addresses part of that problem by keeping outcome assessors and data analysts blinded to group assignment. That separation should protect the integrity of the primary analysis, especially because opioid consumption is an objective endpoint.
Still, the limitation is baked into the procedure itself. A regional block cannot be administered in a fully masked way when the same anesthetist is responsible for performing the technique, and the study does not include a sham block. Subjective pain scores may therefore be more vulnerable to bias than the opioid endpoint, even if the trial measures them. In analgesia research, objective drug use often offers a sturdier readout than self-reported pain intensity alone.
Heterogeneous Surgical Cases May Blur the Signal
The trial enrolls a heterogeneous surgical population, and no stratification by procedure type is planned. That creates a plausible source of confounding because pain burden after one upper abdominal laparoscopic operation may not match another, even when the incisions look similar on paper. A patient undergoing a more extensive procedure may require more analgesia regardless of block efficacy, while a smaller case may need little rescue opioid even without the intervention. Prespecified covariate adjustment is intended to address some of that variation, but statistical adjustment cannot fully replace a more uniform surgical cohort.
This is a familiar challenge in perioperative trials: the anatomy is consistent, but the operative stress is not always the same. The trial’s value will depend on whether the regional block signal is strong enough to emerge above that background heterogeneity. If the difference in 24-hour opioid use is clear despite mixed procedures, the technique could still prove useful in routine practice. If the result is muted, the cause may lie as much in case mix as in block performance.
The protocol does not overclaim benefit. It asks a limited question and uses a measurable endpoint to answer it.
What Clinicians Will Watch When Results Arrive
Because the study centers on immediate postoperative analgesia, the first question will be whether the bilateral block actually lowers opioid consumption during the first day after surgery. If it does, the next issue will be whether that benefit is clinically meaningful enough to justify routine use, training, and procedural time. If it does not, the findings may still be informative by showing how much background analgesia from standardized anesthesia and patient-controlled intravenous medication can already compress the room for improvement.
The protocol is also relevant because it tests a block that sits between theory and bedside practicality. A technically feasible ultrasound-guided technique is only useful if it changes care in a consistent way. Early postoperative opioid use is the right measure for that test because it is immediate, concrete, and tied to outcomes patients feel quickly: pain control, alertness, nausea, and movement.
Why This Trial Matters for Perioperative Pain Strategy
Regional techniques continue to compete on one central question: can they produce dependable analgesia without making perioperative care more complicated? This protocol takes that question seriously. It does not rely on a flashy composite endpoint or a broad quality-of-recovery claim. It measures a direct analgesic consequence and does so under standardized perioperative conditions, with blinding applied where it is methodologically possible.
The result will not settle every question about external oblique intercostal block performance, especially in different procedure types or in settings with different baseline opioid practices. It will, however, provide a focused test of whether the block can reduce 24-hour opioid consumption after major laparoscopic upper abdominal surgery. The unresolved issues are straightforward: how large the analgesic effect will be, whether heterogeneous procedures dilute it, and whether the absence of a sham comparator leaves enough uncertainty in subjective outcomes to limit adoption.
These are the questions the trial is built to answer, and they are the right ones for a protocol at this stage.